StockMarketWire.com - Pharmaceuticals group Hikma Pharmaceuticals forecast its generics business to generate revenue toward the top end of guidance following a 'good' start to the new year that was in line with its expectations.

Full year generics revenue was now expected towards the top end of its guidance range of $770 million to $810 million and core operating margin to be around 20%.

'We have also seen continued demand for certain COVID-19 related products, and a good performance from recent launches, which is more than offsetting increased competition on certain products, in line with our expectations,' the company said.

It maintained full-year guidance for its injectables and branded businesses.

Injectables core revenue is expected to grow in the mid-single digits and core operating margin to be in the range of 37% to 38%.

Branded revenue growth in constant currency is forecast in the mid-single digits.

Interim results for the six months to 30 June 2021 would be released on 6 August 2021.






Story provided by StockMarketWire.com